Drug Type Fusion protein |
Synonyms C3b inhibitor-CD59, KNP 302, KNP-302 |
Target |
Mechanism C3 inhibitors(Complement C3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
dry age-related macular degeneration | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | 30 Jan 2022 |
Immune System Diseases | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | - |